 The secondary aims of this study are to assess whether ziprasidone dose escalation improves psychotic symptoms compared to continued standard treatment as measured by the Positive Symptom Subscale of the PANSS, to assess whether ziprasidone dose escalation improves negative symptoms compared to standard treatment as measured by the Negative Symptom Subscale of the PANSS, to assess whether ziprasidone dose escalation improves depressive symptoms compared to continued standard treatment as measured by the Calgary Depression Rating Scale CDRS, and to assess whether ziprasidone dose escalation improves overall functioning with the Clinical Global Impression - Severity CGI-S, Clinical Global Impression - Improvement CGI-I, Global Assessment of Functioning GAF and the Schizophrenia Cognition Rating Scale SCoRS. 